Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia

被引：15

作者：

Goldsmith, JC

Eller, N

Mikolajczyk, M

Manischewitz, J

Golding, H

Scott, DE

机构：

[1] Immune Deficiency Fdn, Towson, MD USA

[2] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA

来源：

VOX SANGUINIS | 2004年 / 86卷 / 02期

关键词：

anti-vaccinia virus antibodies; immune globulin (intravenous; human); primary immune deficiency; smallpox vaccination;

D O I：

10.1111/j.0042-9007.2004.00397.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background and Objectives Individuals with primary or secondary immune-deficiency diseases may be at risk for vaccinia infection if widespread smallpox-immunization programmes are implemented in the United States of America (USA) for bioterrorism preparedness. The objective of this study was to determine whether commercial immune globulin (intravenous, human) products contain biologically active antibodies to vaccinia that have the potential to protect people, with immune deficiencies, from complications of vaccinia. Materials and Methods Eight currently United States (US)-licensed and two European intravenous immunoglobulin (IVIG) products were tested in a vaccinia plaque-reduction neutralization assay. The in vivo activity of five of these lots was assessed in severely immune-deficient mice. Results All tested products contained neutralizing anti-vaccinia activity, in vitro and in vivo. Conclusions The use of IVIG by individuals with inherited or acquired humoral immune deficiencies may provide some protection if they are inadvertently exposed to vaccinia.

引用

页码：125 / 129

页数：5

共 24 条

[1] ANTIGENIC DIFFERENCE BETWEEN INTRACELLULAR AND EXTRACELLULAR RABBITPOX VIRUS [J].

APPLEYARD, G ;

HAPEL, AJ ;

BOULTER, EA .

JOURNAL OF GENERAL VIROLOGY, 1971, 13 (OCT) :9-+

[2]

*BAXT CORP, 1991, PACK INS VACC IMM GL

[3]

Boulter E A, 1973, Prog Med Virol, V16, P86

[4]

CDC, 2001, Morbidity and Mortality Weekly Report, V50, P1

[5]

FENNER F, 1988, SMALLPOX ITS ERADICA, P308

[6]

Frelinger JA, 2002, NEW ENGL J MED, V347, P689

[7] Duration of antiviral immunity after smallpox vaccination [J].

Hammarlund, E ;

Lewis, MW ;

Hansen, SG ;

Strelow, LI ;

Nelson, JA ;

Sexton, GJ ;

Hanifin, JM ;

Slifka, MK .

NATURE MEDICINE, 2003, 9 (09) :1131-1137

[8] A recombinant vaccinia-rabies virus in the immunocompromised host: Oral innocuity, progressive parenteral infection, and therapeutics [J].

Hanlon, CA ;

Niezgoda, M ;

Shankar, V ;

Niu, HS ;

Koprowski, H ;

Rupprecht, CE .

VACCINE, 1997, 15 (02) :140-148

[9] Smallpox as a biological weapon - Medical and public health management [J].

Henderson, DA ;

Inglesby, TV ;

Bartlett, JG ;

Ascher, MS ;

Eitzen, E ;

Jahrling, PB ;

Hauer, J ;

Layton, M ;

McDade, J ;

Osterholm, MT ;

O'Toole, T ;

Parker, G ;

Perl, T ;

Russell, PK ;

Tonat, K .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (22) :2127-2137

[10]

Hooper J. A, 1997, INTRAVENOUS IMMUNOGL, P37

← 1 2 3 →